Stay updated with breaking news from Editas Engineered Ascas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease FDA removed partial clinical hold for the RUBY trial in EDIT-301 First clinical use of Editas-engineered... | July 27, 2022
Editas Medicine Announces First Quarter 2022 Results and Business Updates - read this article along with other careers information, tips and advice on BioSpace
Appointed Gilmore O’Neill as CEO effective June 1, 2022; James C. Mullen to serve as Executive Chairman
Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a...